Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...

The British Standards Institution (BSI) will release new fire safety guidance on 27th November 2024, marking a significant ...

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...

Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with ...

I reviewed LastPass, a low-cost password manager with that supports a wide range of devices and offers convenient login ...

Cyber security in Germany remains serious - the end of the coalition threatens to remove important laws. Federal Interior ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

BETHLEHEM, Pa. -- Thursday at Freedom High School, BSI Corporate Benefits announced a new scholarship. Over the next 5 years, ...

This follows a successful trial involving Malaysian bus commuters and motorcyclists that began in June and ends this month, ...